Regulus Therapeutics (RGLS)

$1.24 -0.04 (-3.12%)
Market Cap 83.84M
Revenue (ttm) 0.00
Net Income (ttm) -30.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 330,100
Avg Vol 319,470
Day's Range N/A - N/A
Shares Out 65.50M
Stochastic %K 15%
Beta 1.60
Analysts Strong Sell
Price Target $10.80

Latest News on RGLS

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Nov 26, 2024, 8:00 AM EST - 7 weeks ago

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Nov 7, 2024, 4:05 PM EST - 2 months ago

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 8, 2024, 8:00 AM EDT - 3 months ago

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Aug 28, 2024, 8:00 AM EDT - 5 months ago

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Aug 8, 2024, 4:05 PM EDT - 5 months ago

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Aug 6, 2024, 8:00 AM EDT - 5 months ago

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 24, 2024, 7:00 AM EDT - 7 months ago

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Jun 4, 2024, 8:00 AM EDT - 8 months ago

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

May 16, 2024, 8:00 AM EDT - 8 months ago

Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

May 9, 2024, 4:05 PM EDT - 9 months ago

Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

May 6, 2024, 8:00 AM EDT - 9 months ago

Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Apr 30, 2024, 8:00 AM EDT - 9 months ago

Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Apr 10, 2024, 12:51 PM EDT - 10 months ago

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Mar 21, 2024, 4:05 PM EDT - 10 months ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Mar 12, 2024, 6:32 AM EDT - 11 months ago

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mar 12, 2024, 6:30 AM EDT - 11 months ago

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jan 2, 2024, 4:05 PM EST - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Nov 22, 2023, 8:00 AM EST - 1 year ago

Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Nov 9, 2023, 4:05 PM EST - 1 year ago

Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Oct 19, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 13, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Aug 23, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Aug 8, 2023, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Jul 18, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Jun 27, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Jun 23, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D.

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Jun 20, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

Regulus Therapeutics Strengthens Research & Development Leadership

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Strengthens Research & Development Leadership

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

May 16, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

May 11, 2023, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates

Regulus Therapeutics Announces $15 Million Private Placement of Equity

Apr 13, 2023, 8:00 AM EDT - 1 year ago

Regulus Therapeutics Announces $15 Million Private Placement of Equity

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Apr 12, 2023, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Mar 23, 2023, 4:05 PM EDT - 1 year ago

Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

Feb 9, 2023, 8:00 AM EST - 2 years ago

Regulus Therapeutics to Present at the SVB Securities Global Biopharma Conference

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2023, 4:05 PM EST - 2 years ago

Regulus Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Regulus Therapeutics Announces Resignation of Board Member

Dec 12, 2022, 8:00 AM EST - 2 years ago

Regulus Therapeutics Announces Resignation of Board Member

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations

Nov 29, 2022, 8:00 AM EST - 2 years ago

Regulus Therapeutics Announces Appointments of Industry Veterans, Drs. Rekha Garg and Claire Padgett, to Lead Clinical Development, Regulatory and Clinical Operations

Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript

Nov 10, 2022, 9:49 PM EST - 2 years ago

Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

Nov 10, 2022, 4:05 PM EST - 2 years ago

Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates

Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call

Nov 3, 2022, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Nov 2, 2022, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

Oct 27, 2022, 4:05 PM EDT - 2 years ago

Regulus Therapeutics Announces Poster Presentation at ASN Kidney Week 2022

Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Sep 12, 2022, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics to Participate in Upcoming Investor Conferences

Sep 2, 2022, 4:05 PM EDT - 2 years ago

Regulus Therapeutics to Participate in Upcoming Investor Conferences

Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 6:51 PM EDT - 2 years ago

Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Aug 11, 2022, 4:10 PM EDT - 2 years ago

Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call

Aug 4, 2022, 8:00 AM EDT - 2 years ago

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call